title: Insights towards sulfonamide drug specificity in α-carbonic anhydrases.
abstract: Carbonic anhydrases (CAs, EC 4.2.1.1) are a group of metalloenzymes that play important roles in carbon metabolism, pH regulation, CO2 fixation in plants, ion transport etc., and are found in all eukaryotic and many microbial organisms. This family of enzymes catalyzes the interconversion of CO2 and HCO3(-). There are at least 16 different CA isoforms in the alpha structural class (α-CAs) that have been isolated in higher vertebrates, with CA isoform II (CA II) being ubiquitously abundant in all human cell types. CA inhibition has been exploited clinically for decades for various classes of diuretics and anti-glaucoma treatment. The characterization of the overexpression of CA isoform IX (CA IX) in certain tumors has raised interest in CA IX as a diagnostic marker and drug target for aggressive cancers and therefore the development of CA IX specific inhibitors. An important goal in the field of CA is to identify, rationalize, and design potential compounds that will preferentially inhibit CA IX over all other isoforms of CA. The variations in the active sites between isoforms of CA are subtle and this causes non-specific CA inhibition which leads to various side effects. In the case of CA IX inhibition, CA II along with other isoforms of CA provide off-target binding sites which is undesirable for cancer treatment. The focus of this article is on CA IX inhibition and two different structural approaches to CA isoform specific drug designing: tail approach and fragment addition approach.
authors.affiliation: Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, 1600 SW Archer Rd., PO Box 100245, Gainesville, FL 32610, USA.
authors.forename: Mayank
authors.initials: M
authors.lastname: Aggarwal
authors.forename: Bhargav
authors.initials: B
authors.lastname: Kondeti
authors.forename: Robert
authors.initials: R
authors.lastname: McKenna
mesh_terms: D001665:Binding Sites; D002257:Carbonic Anhydrase Inhibitors / Q000737:chemistry* / Q000378:metabolism; D002256:Carbonic Anhydrases / Q000737:chemistry* / Q000378:metabolism; D020134:Catalytic Domain; D030562:Databases, Protein; D015195:Drug Design; D006801:Humans; D007527:Isoenzymes / Q000737:chemistry / Q000378:metabolism; D009369:Neoplasms / Q000201:enzymology / Q000473:pathology; D011485:Protein Binding; D013449:Sulfonamides / Q000737:chemistry* / Q000378:metabolism
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D007527:Isoenzymes; D013449:Sulfonamides; D002256:Carbonic Anhydrases